HCW Biologics (HCWB) EBIT Margin (2022 - 2026)
HCW Biologics' (HCWB) quarterly EBIT Margin came in at 2335.57% in Q2 2026, up 5055110.0% on a YoY basis from N/an in Q2 2025, and up 85.86% quarter-over-quarter from 16519.15% in Q4 2025.
Powered by 
Analysis
HCW Biologics (HCWB) EBIT Margin (2022 - 2026) Analysis & Trends
HCW Biologics (HCWB) has reported EBIT Margin for 5 consecutive years, with 2335.57% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBIT Margin rose 5055110.0% year-over-year to 2335.57%; the trailing twelve-month figure through Jun 2026 stood at 7786.5% (down 631420.0% YoY), and the FY2025 full-year result was 24270.74%, down 2312314.0% from the prior year.
- EBIT Margin advanced to 2335.57% in Q2 2026 per HCWB's latest filing, from 16519.15% in the prior quarter.
- Across five years, EBIT Margin topped out at 60.33% in Q1 2022 and bottomed at 52886.67% in Q2 2025.
- Historically, EBIT Margin has averaged 8990.02% across 5 years, with a median of 813.31% in 2023.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin sank 5044086 bps in 2025, then surged 5055110 bps in 2026.
- Over 5 years, EBIT Margin stood at 422.45% in 2022, then plunged by 93 bps to 813.31% in 2023, then climbed by 2 bps to 797.23% in 2024, then slumped by 1972 bps to 16519.15% in 2025, then surged by 86 bps to 2335.57% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 2335.57%, 16519.15%, and 21095.26% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | -25,380.93% |
| 10 | HCW Biologics | 3.24 Mn | 2.50 Mn | -93,887.00 | -2,335.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,335.57% |
| Dec 31, 2025 | -16,519.15% |
| Sep 30, 2025 | -21,095.26% |
| Jun 30, 2025 | -52,886.67% |
| Mar 31, 2025 | -38,811.49% |
| Dec 31, 2024 | -797.23% |
| Sep 30, 2024 | -864.06% |
| Jun 30, 2024 | -2,445.81% |
| Mar 31, 2024 | -665.09% |
| Dec 31, 2023 | -813.31% |
| Sep 30, 2023 | -595.23% |
| Jun 30, 2023 | -724.22% |
| Mar 31, 2023 | -12,798.92% |
| Dec 31, 2022 | -422.45% |
| Sep 30, 2022 | -222.20% |
| Jun 30, 2022 | -773.36% |
| Mar 31, 2022 | -60.33% |